Preview Mode Links will not work in preview mode

Mar 15, 2024

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 2: Triple-Negative Breast Cancer — Priyanka Sharma, MD


CME information and select...


Mar 15, 2024

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 1: HER2-Positive Breast Cancer — Ian E Krop, MD, PhD


CME information and select...


Mar 15, 2024

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics: 
  • Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00)
  • HER2-Positive Breast Cancer — Dr Krop (12:30)
  • Triple-Negative Breast...


Mar 13, 2024

Featuring perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics:

First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab

  • Case: A man in his late 80s with recurrent unresectable...


Mar 11, 2024

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics:

  • Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00)
  • Efficacy and safety of oral SERDs in patients with ER-positive metastatic...